Key result
Combination therapy with angiotensin receptor antagonists and calcium channel blockers provides greater antihypertensive efficacy than monotherapy and lacks adverse metabolic effects.
Why the study?
Does combination therapy with angiotensin receptor blockers and calcium channel blockers improve blood pressure control and adherence in patients with hypertension compared to monotherapy?
Does combination therapy with angiotensin receptor blockers and calcium channel blockers improve blood pressure control and adherence in patients with hypertension compared to monotherapy?
Combination therapy with ARBs and CCBs is an effective, well-tolerated strategy for hypertension management that aligns with European guidelines and improves adherence when used in fixed-dose formulations.
Answers are grounded in this paper and cite their sources.
May support ARB-CCB combinations in hypertension; leaves open prospective RCTs to confirm adherence and outcome benefits.
The 2007 European Society of Hypertension-European Society of Cardiology guidelines on hypertension management placed increased emphasis on the need for obtaining satisfactory blood pressure (BP) control in all patients with high BP, and in particular in those with a higher cardiovascular risk. According to these guidelines, the majority of patients will require the use of combination antihypertensive treatment to achieve their BP goals. This review highlights the factors that should be considered when choosing a combination therapy, including efficacy, tolerability, metabolic effects, and additional organoprotective benefits. Several possible combinations are proposed by the European Society of Hypertension-European Society of Cardiology guidelines. Among them, the combination of angiotensin receptor antagonists with calcium channel blockers has been shown to provide well-tolerated antihypertensive efficacy, which is greater than that of monotherapy with either agent, and lacks adverse metabolic effects. The development of fixed-dose angiotensin receptor blocker-calcium channel blocker therapy offers additional benefits in terms of adherence to treatment.
No takes yet. Share an insight, caveat, or question.
Gianfranco Parati (2009) conducted a review in Hypertension. Angiotensin receptor blocker-calcium channel blocker combinations vs. Monotherapy was evaluated. Combination therapy with angiotensin receptor antagonists and calcium channel blockers provides greater antihypertensive efficacy than monotherapy and lacks adverse metabolic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: